For example, a phase 1/2 study using autologous CRISPR/Cas9-modified CD34+ human hematopoietic stem and progenitor cells for the treatment of beta thalassemia has already been approved (https://clinicaltrials.gov/ct2/show/NCT03655678). Here, CD34 is linked to beta thalassemia.